Eledon Pharmaceuticals (NASDAQ:ELDN – Get Free Report) posted its earnings results on Thursday. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.32), Zacks reports. During the same quarter in the previous year, the firm posted ($1.00) EPS.
Eledon Pharmaceuticals Stock Up 0.6 %
Shares of ELDN traded up $0.02 during mid-day trading on Friday, hitting $3.46. The company had a trading volume of 56,806 shares, compared to its average volume of 275,260. The business’s 50-day simple moving average is $4.18 and its 200-day simple moving average is $3.85. Eledon Pharmaceuticals has a 1-year low of $1.52 and a 1-year high of $5.54. The stock has a market cap of $206.70 million, a PE ratio of -1.73 and a beta of 0.80.
Analyst Ratings Changes
Separately, Guggenheim began coverage on shares of Eledon Pharmaceuticals in a research note on Tuesday, January 28th. They set a “buy” rating and a $9.00 price target on the stock.
About Eledon Pharmaceuticals
Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).
Featured Stories
- Five stocks we like better than Eledon Pharmaceuticals
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- FedEx Delivers Another Crushing Blow to Its Stock Price
- What Are Growth Stocks and Investing in Them
- Analysts Stay Bullish on Rocket Lab as Signs of a Bottom Emerge
- Investing in Commodities: What Are They? How to Invest in Them
- Micron Stock Will Retest All-Time Highs This Year
Receive News & Ratings for Eledon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eledon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
